Evidence map›Paper›PMID 31600443›Full record

ArticleJournal of the American Chemical Society2019

Pyonitrins A-D: Chimeric Natural Products Produced by

Emily Mevers, Josep Saurí, Eric J N Helfrich, Matthew Henke, Kenneth J Barns, Tim S Bugni, David Andes, Cameron R Currie, Jon Clardy

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Naturally Occurring Organohalogen Compounds-A Comprehensive Review.Progress in the chemistry of organic natural products · 2023
    Review
  7. Metabologenomics analysis ofFrontiers in microbiology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emily MeversDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , 240 Longwood Avenue , Boston , Massachusetts 02115 , United States.ORCID 0000-0001-7986-5610
Josep SauríStructure Elucidation Group, Process and Analytical Research and Development , Merck & Co., Inc. , 33 Avenue Louis Pasteur , Boston , Massachusetts 02115 , United States.
Eric J N HelfrichDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , 240 Longwood Avenue , Boston , Massachusetts 02115 , United States.
Matthew HenkeDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , 240 Longwood Avenue , Boston , Massachusetts 02115 , United States.
Kenneth J BarnsPharmaceutical Sciences Division, School of Pharmacy , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States.
Tim S BugniPharmaceutical Sciences Division, School of Pharmacy , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States.
David AndesDepartment of Medicine , University of Wisconsin School of Medicine and Public Health , Madison , Wisconsin 53705 , United States.
Cameron R CurrieDepartment of Bacteriology , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States.
Jon ClardyDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , 240 Longwood Avenue , Boston , Massachusetts 02115 , United States.ORCID 0000-0003-0213-8356

Funding

Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsU19AI142720 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SAFDAR, NASIA · 2019 to 2023
$30.1M
Metabolomics driven discovery of drug leads from symbiotic bacteriaU19AI109673 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, CURRIE, CAMERON ROBERT · 2014 to 2018
$16.2M
NIAID NIH HHS U19 AI109673NIAID NIH HHS U19 AI142720
6 · The paper itself

Abstract

Bacterial symbionts frequently provide chemical defenses for their hosts, and such systems can provide discovery pathways to new antifungals and structurally intriguing metabolites. This report describes a small family of naturally occurring small molecules with chimeric structures and a mixed biosynthesis that features an unexpected but key nonenzymatic step. An insect-associated

Indexed as

AnimalsAntifungal AgentsBacterial ProteinsBiological ProductsBiosynthetic PathwaysCandida albicansCandidiasisChromatography, High Pressure LiquidDrug Evaluation, PreclinicalMagnetic Resonance SpectroscopyMiceMolecular StructurePhenolsPseudomonasPyrrolnitrinThiazolesAntifungal AgentsBacterial ProteinsBiological ProductsPhenolspyochelinPyrrolnitrinThiazoles

Identifiers

PMID31600443
PMCPMC6823628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.